Emerging from the UK, retatrutide, a new molecule, is creating considerable interest within the healthcare community regarding its promise for body management . This dual GIP and GLP-1 receptor agonist seems to deliver a substantial advantage over current therapies, showing promising results in early clinical trials . Researchers think its unique m